Nintedanib-d3

(Synonyms: BIBF 1120-d3; Intedanib-d3)
Customer Review

Based on 1 Customer Validation

Nintedanib-d3 (BIBF 1120-d3; Intedanib-d3) is the deuterated-labeled Nintedanib (HY-50904). Nintedanib is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease.

For research use only. We do not sell to patients.

  • Purity : 99.78%
  • CAS No.: 1624587-84-3
  • Formula: C31H30D3N5O4
  • Molecular Weight:542.64
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00